Jeffrey Dierks - Jan 6, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Signature
/s/ Christian Ulrich, Attorney-in-fact for Jeffrey Dierks
Stock symbol
HRMY
Transactions as of
Jan 6, 2022
Transactions value $
-$196,910
Form type
4
Date filed
1/10/2022, 03:07 PM
Previous filing
Nov 3, 2021
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $50.3K +6.13K $8.22* 6.13K Jan 6, 2022 Direct
transaction HRMY Common Stock Sale -$55.4K -1.4K -22.84% $39.60 4.73K Jan 6, 2022 Direct F1, F2
transaction HRMY Common Stock Sale -$174K -4.3K -91.03% $40.53 424 Jan 6, 2022 Direct F1, F3
transaction HRMY Common Stock Sale -$17.5K -424 -100% $41.23 0 Jan 6, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -3.69K -27.48% $0.00 9.74K Jan 6, 2022 Common Stock 3.69K $8.22 Direct F5
transaction HRMY Stock Option Options Exercise $0 -2.44K -33.34% $0.00 4.87K Jan 6, 2022 Common Stock 2.44K $8.22 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.04. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $41.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $41.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares on October 1, 2022.
F6 The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2022.